Article
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Cancer discovery - 1 Sept 2014
Chiron David, Di Liberto Maurizio, Martin Peter, Huang Xiangao, Sharman Jeff, Blecua Pedro, Mathew Susan, Vijay Priyanka, Eng Ken, Ali Siraj, Johnson Amy, Chang Betty, Ely Scott, Elemento Olivier, Mason Christopher E, Leonard John P, Chen-Kiang Selina
Abstract excerpt
UNLABELLED: Despite the unprecedented clinical activity of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib in mantle cell lymphoma (MCL), acquired resistance is common. By longitudinal integrative whole-exome and whole-transcriptome sequencing and targeted sequencing, we identified the first relapse-specific C481S mutation at the ibrutinib binding site of BTK in MCL cells at progression following a durable...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.